PolyCore Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
PolyCore Therapeutics was a Philadelphia biopharmaceutical company, spun out of Drexel University, developing treatments for dyskinesia and cognitive impairment associated with neurodegenerative disorders. Its lead approach used G-protein-biased dopamine D3 receptor agonists aimed at Parkinson's patients suffering motor symptoms and levodopa-induced dyskinesia. The company raised venture rounds and NIH grants through 2022.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
PolyCore Therapeutics was founded in Philadelphia as a Drexel University spin-out focused on CNS disease therapies.
- NIH grant
The company received a $1.5 million grant from the National Institutes of Health in August 2020.
- Seed round
PolyCore raised a seed round in April 2022 led by Xontogeny, with Ben Franklin Technology Partners participating.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.